Search Results
Your search for The ,The matches 34595 pages
Showing 7751 - 7800Novel Therapies Under Study in Acute Myeloid Leukemia
Newly identified genetic abnormalities in acute myeloid leukemia (AML), as well as therapies that can target some of those abnormalities, are now available as the landscape for treatment continues to evolve. During the 2021 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic...
Friends of Cancer Research Releases White Paper on Optimizing Dosing in Oncology Drug Development
During its virtual Annual Meeting 2021 held on November 9 and 10, Friends of Cancer Research (Friends) urged all stakeholders in the cancer community to work together to optimize dosing in oncology drug development to maximize benefit for patients and reduce treatment toxicity, and to abandon the...
Expert Point of View: Steven J. Chmura, MD, PhD
At a press conference at the 2021 ASTRO Annual Meeting, Steven J. Chmura, MD, PhD, Professor of Radiation Oncology and Scientific Director of the Cancer Clinical Trials Office, University of Chicago, commented on the CURB study results. “Most trials of stereotactic body radiation therapy (SBRT)...
Can SBRT to Selected Sites of Limited Progression or Oligoprogression Extend Progression-Free Survival in Advanced Lung Cancer but Not Breast Cancer?
Stereotactic body radiation therapy (SBRT) lengthens progression-free survival for patients with advanced lung cancer who have oligoprogression (ie, tumors that have not been fully responsive to systemic chemotherapy or immunotherapy), according to an interim analysis of the CURB oligoprogression...
NETTER-1 Trial: Final Overall Survival Analysis of Lu-177 Dotatate Plus Long-Acting Octreotide vs High-Dose Long-Acting Octreotide for Midgut Neuroendocrine Tumors
As reported in The Lancet Oncology by Jonathan R. Strosberg, MD, and colleagues, the final overall survival analysis of the pivotal phase III NETTER-1 trial has shown an approximate 12-month benefit with the addition of lutetium-177 (Lu-177) dotatate to long-acting octreotide in patients with...
Study Finds Unique Genomic and Molecular Features in Young Adult Patients With Cancer
Young adults diagnosed with cancer may require different treatments than those received by older patients, according to a study that systematically compared the genomes of 14 different types of cancers affecting both younger and older adults. The results, published by Lee et al in Cell Reports,...
Expert Point of View: Elizabeth Nichols, MD
Invited discussant Elizabeth Nichols, MD, of the University of Maryland, School of Medicine, Baltimore, commented on both the phase II TRIUMPH-T and the phase III MC1635 trials. “There are multiple techniques in use for accelerated partial breast irradiation. Optimal dose and fractionation are...
Accelerated Radiation Therapies Move Forward in Early Breast Cancer
Two studies reported at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting provide evidence in support of the use of accelerated radiation therapies as safe alternatives to standard radiotherapy options following breast-conserving surgery. The phase III MC1635 trial showed...
Durable Responses in Metastatic NSCLC: Are We Getting Closer to a Cure?
In the United States, the incidence-based mortality related to non–small cell lung cancer (NSCLC) has decreased by approximately 3% each year since 2008 in men; during the same period, the mortality in women decreased by 2% to 4% annually.1 Although multiple factors are likely responsible for the...
From Cancer Survivor to Citizen Astronaut
When I was diagnosed with osteosarcoma of my left femur nearly 20 years ago, I remember telling my parents that I didn’t want to die. The diagnosis was terrifying because all the people I knew who had cancer had passed away, and I thought this cancer would kill me, too. That evening, my dad went...
Expert Point of View: Sophia C. Kamran, MD
Sophia C. Kamran, MD, Assistant Professor of Radiation Oncology at Massachusetts General Hospital, commented on the NRG Oncology GU003 study at a press conference where this abstract was discussed. Dr. Kamran was not involved in this trial. “This is a potentially practice-changing study in an area ...
Shorter-Course Radiation Therapy: A New Practice Standard After Prostatectomy?
Hypofractionated radiotherapy to the prostate bed proved to be noninferior to conventionally fractionated radiotherapy after prostatectomy regarding gastrointestinal and genitourinary side effects, according to the results of the phase III NRG Oncology GU003 trial, presented at the 2021 American...
Long-Term Outcomes With Chemoradiotherapy Before vs After Chemotherapy in the Total Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Long-term results of a German phase II trial (CAO/ARO/AIO-12) reported in JAMA Oncology by Fokas et al showed similar disease outcomes, chronic toxicity, and quality of life with chemoradiotherapy before vs after chemotherapy in the total neoadjuvant treatment of patients with locally advanced...
Novel Therapies Under Study in Acute Myeloid Leukemia
Newly identified genetic abnormalities in AML have led to novel therapies that can target some of them, as the landscape for treatment continues to evolve. During the 2021 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic Malignancies, Alice S. Mims MD, presented updates in...
AI-Based Breast Cancer Risk Model: Multi-institution Validation
In a study reported in the Journal of Clinical Oncology, Yala et al found that using the artificial intelligence (AI)-based Mirai model across diverse populations resulted in consistently accurate predictions of breast cancer risk based on screening mammography. Study Details In the study, Mirai...
Early Study Examines Potential Benefits of a Fasting-Mimicking Diet in Patients With Cancer
A severely calorie-restricted, low-carbohydrate, low-protein, 5-day dietary regimen that mimics fasting was shown to be safe and feasible, and it resulted in a decrease of blood glucose and growth factor concentration, a reduction in peripheral blood immunosuppressive cells, and enhanced intratumor ...
Exercise Program May Help to Reduce Upper Limb Disability After Breast Cancer Surgery
Arm and shoulder disability and pain that some women who have had breast cancer surgery experience as a side effect of their procedure may be reduced by following a physiotherapy-led exercise program, according to a new study published by Bruce et al in The BMJ. The report showed an improvement in...
Evorpacept Alone and Combined With Pembrolizumab or Trastuzumab for Advanced Solid Tumors
In the phase I ASPEN-01 study reported in The Lancet Oncology, Nehal Lakhani, MD, and colleagues found evidence of activity of the CD47-blocking protein evorpacept in combination with pembrolizumab or trastuzumab for the treatment of advanced solid tumors. As stated by the investigators, “Both...
SITC 2021: New Data in Immunotherapy
The Society for Immunotherapy of Cancer (or SITC) held its Annual Meeting from November 10 to November 14. On this episode, we’ll hear from two researchers who presented data at the SITC meeting.
Newer Agents on the Horizon for Refractory or Relapsed DLBCL
Although treating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains challenging, some newer therapies on the horizon offer promise, including bispecific antibodies, anti-CD47 antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T-cell therapy,...
Yongbae Kim, MD, on Elective Internal Mammary Node Irradiation in Women With Node-Positive Breast Cancer: Results of a Randomized Phase III Trial
Yongbae Kim, MD, of the Yonsei Cancer Center and Yonsei University College of Medicine, discusses findings that showed the use of internal mammary area irradiation (IMNI) in regional nodal irradiation did not significantly improve disease-free survival for women with node-positive breast cancer....
Ronald S. Go, MD, on Managing Histiocytic Neoplasms: New NCCN Guidelines
Ronald S. Go, MD, of Mayo Clinic Cancer Center, discusses the new NCCN Clinical Practice Guidelines in Oncology for the most common types of histiocytic neoplasms in adults—Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease, all considered rare among hematologic...
2021 State of Lung Cancer Report Finds Survival Has Increased but Remains Significantly Lower for People of Color
The new 2021 State of Lung Cancer report reveals that the 5-year survival rate for lung cancer increased from 14.5% nationally to 23.7%, yet it remains significantly lower among communities of color. The American Lung Association’s fourth annual report also highlights how the toll of lung cancer...
Model May Help Identify Subtypes of Multiple Myeloma
Researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for subtypes of multiple myeloma. They also identified potential targeted treatments based on the findings, which were reported by...
Changes in PSA Screening After 2017 USPSTF Guidance Revision
In a study reported in JAMA Oncology, Michael S. Leapman, MD, and colleagues found that prostate-specific antigen (PSA) screening for prostate cancer has increased since the 2017 publication of the U.S. Preventive Services Task Force (USPSTF) draft guidance endorsing individual decision-making for...
Effect of Embedding a Palliative Care Nurse Practitioner in an Oncology Clinic
In a single-center study reported in JCO Oncology Practice, D’Ambruoso et al found that their Integrated Palliative Care and Oncology Program, which included the embedding of a palliative care nurse practitioner (PC-NP) in an oncology clinic, resulted in marked improvements in aspects of palliative ...
FDA Expands Eligibility for COVID-19 Vaccine Boosters
On November 19, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals aged 18 years and older after completion of primary vaccination with any ...
Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?
Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses the evolving treatment paradigm for patients with newly diagnosed multiple myeloma in which clinical trials are suggesting the addition of a fourth drug to induction treatment regimens and new drug classes are improving treatment for...
Study Examines Availability of All-Trans Retinoic Acid in U.S. Hospitals
New research published by Geer et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that fewer than one-third of hospitals in the United States had immediate availability of all-trans retinoic acid (ATRA), a crucial blood cancer medication. ATRA is initiated early in the...
Immunogenicity of COVID-19 Vaccination in Patients Receiving Systemic Therapy for Solid Tumors
In a Dutch study (VOICE) reported in The Lancet Oncology, Sjoukje F. Oosting, MD, and colleagues found that the mRNA-1273 (Moderna) COVID-19 vaccine produced adequate antibody responses in a majority of patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumors, with...
Development of Phenotypic Spectrum Categorization for Li-Fraumeni Syndrome
In a study reported in JAMA Oncology, Kratz et al analyzed data from the International Agency for Research on Cancer (IARC) TP53 Database to define a phenotypic spectrum categorization for Li-Fraumeni syndrome. As stated by the investigators, “Li-Fraumeni syndrome is a cancer predisposition...
Brain Substructure–Informed Radiotherapy Planning May Improve Neurocognitive Outcomes in Pediatric Patients With Medulloblastoma
In an analysis from the single-institution phase III SJMB03 trial reported in the Journal of Clinical Oncology, Acharya et al found that increasing radiation doses to the corpus callosum, frontal white matter, and hippocampus were associated with neurocognitive impairment in pediatric patients...
FDA Approves Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma
On November 17, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of disease recurrence following nephrectomy or nephrectomy and resection of metastatic lesions....
Digital Symptom Monitoring System May Improve Patients’ Symptom Control and Physical Function During Cancer Therapy
A digital symptom monitoring system in which patients undergoing cancer treatment could report symptoms through weekly at-home surveys resulted in better symptom control and physical function, as well as improved communication with their medical team, according to results from a study by Basch et...
Immunotherapy Followed by Targeted Therapy Yields Greater Overall Survival in Patients With BRAF V600–Mutated Advanced Melanoma
Patients with BRAF V600–mutated advanced melanoma who received an immunotherapy regimen of nivolumab/ipilimumab followed by targeted therapy with dabrafenib/trametinib experienced greater overall survival (72%) compared with patients receiving the converse sequence (52%). According to the study...
Thomas Gruenberger, MD, Shares Thoughts on Radiotherapy for Colorectal Liver Metastases
Invited discussant of the phase III EPOCH trial, Thomas Gruenberger, MD, a surgical oncologist at the Clinic Favoriten, Health Network Vienna, noted that the trial’s “intention was fulfilled,” thus making it the “first positive phase III trial that prolonged both progression-free and hepatic...
STAMPEDE Trial: Quality of Life With Abiraterone vs Docetaxel in Advanced Hormone-Sensitive Prostate Cancer
In an analysis from the STAMPEDE trial reported in the Journal of Clinical Oncology, Rush et al found that global quality of life was better with abiraterone acetate vs docetaxel, both given with prednisone/prednisolone and standard-of-care androgen-deprivation therapy, in men with locally advanced ...
For Liver Metastases, Transarterial Radioembolization With Yttrium-90 Plus Chemotherapy May Delay Disease Progression
In the international phase III EPOCH trial, patients with colorectal liver metastases who experienced disease progression on first-line therapy derived significant benefit from treatment with transarterial yttrium Y-90 radioembolization in combination with systemic chemotherapy, according to Mary...
Association of KRAS Variants With Outcomes After Curative Resection of Intrahepatic Cholangiocarcinoma
In a Chinese single-institution cohort study reported in JAMA Surgery, Zhou et al found that the presence of somatic G12 KRAS variants was associated with poorer overall and disease-free survival in patients who had undergone curative resection of intrahepatic cholangiocarcinoma. Study Details The ...
Study Reveals Genomic Differences Between 14 Tumor Types in Younger vs Older Adults
The results of a study published by Lee et al in Cell Reports suggest that several genetic hallmarks may play key roles in identifying precise treatment options for young adult patients with cancer. The investigators, who systematically compared the genomes of 14 different types of cancers that...
French Study Finds COVID-19 Vaccine Effective in Patients With Lung Cancer
In a new study published by Gounant et al in the Journal of Thoracic Oncology, researchers from France showed that SARS–CoV-2 vaccines are safe and effective in patients with thoracic cancer, most of whom are immunized after two doses. A third shot given to 11% of patients with persistent low...
Treatment Adherence, Toxicity, and Outcomes With Adjuvant Fluoropyrimidine Plus Oxaliplatin in Early-Onset Colorectal Cancer
In an analysis of data from the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) database reported in the Journal of Clinical Oncology, Fontana et al found a greater risk of relapse and cancer-specific mortality after adjuvant fluoropyrimidine/oxaliplatin chemotherapy in patients...
Incidence of Pancreatic Cancer in the United States by Age and Sex, 2000–2018
In a study reported in a research letter in JAMA, Gaddam et al found that the incidence of pancreatic cancer has increased in both men and women between 2000 and 2018, with a greater relative increase being observed in younger women. Pancreatic cancer incidence rates per 100,000 population...
Numerous Regimens Proposed for Relapsed or Refractory Myeloma
Although patients with multiple myeloma can respond to initial treatment, once a patient has had three or four different types of therapy, and the disease is deemed relapsed or refractory, treatment becomes more complicated. This is related to both clinical characteristics, as patients may develop...
Study Explores Method to Selectively Grow Tumor-Targeting T Cells for Cancer Therapy
A preclinical study published by Arnaud et al in Nature Biotechnology has demonstrated the utility and efficacy of a highly efficient method to generate large numbers of immune cells specifically engineered to recognize neoantigens and destroy the tumors that express them. Developed by a team of...
FDA Approves Ropeginterferon alfa-2b-njft for Adults With Polycythemia Vera
The U.S. Food and Drug Administration (FDA) has approved ropeginterferon alfa-2b-njft (Besremi) for the treatment of adults with polycythemia vera. The new agent is a monopegylated, long-acting interferon, which exhibits its cellular effects in polycythemia vera in the bone marrow. Ropeginterferon...
Expert Point of View: Sophia C. Kamran, MD
“Regarding Dr. Nguyen’s study, genomic classifiers are here. They are the future of our field for personalized prostate cancer therapy,” stated Sophia C. Kamran, MD, Assistant Professor of Radiation Oncology at Massachusetts General Hospital, speaking at a press conference where this abstract was...
U.S. Multisociety Task Force on Colorectal Cancer Releases Updated Screening Recommendations
The U.S. Multisociety Task Force on Colorectal Cancer—representing the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy—has updated its colorectal cancer screening recommendations, which were last published...
Use of Genomic Classifier Score May Help to Personalize Therapy for Men With High-Risk Prostate Cancer
A 22-genomic classifier (the Decipher score) was able to predict the course of disease in men with high-risk prostate cancer, according to a patient-level meta-analysis of three randomized clinical trials presented at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 Use of...
Immunogenicity of SARS–CoV-2 Vaccines in Patients With Cancer
In a single-institution prospective cohort study (CANVAX Cohort Study) reported in the Journal of Clinical Oncology, Naranbhai and colleagues assessed the immunogenicity of SARS–CoV-2 vaccines in patients with cancer. They found that immunogenicity varied among vaccines and that both antibody...
